Moreover, genetic depletion or pharmacological inhibition of BCL-xL led to increased apoptotic death and enhanced cisplatin sensitization of bladder cancer cells [48,49,50]. This evidence concerns the gene BCL2L1 and urinary bladder carcinoma.